Navigation Links
White Nose Syndrome: Is Pennsylvania Next?
Date:5/9/2008

ll-footed bats."

The Game Commission will have a chance to shed light on WNS as soon as this summer when bats head to Pennsylvania maternity roosts, such as Canoe Creek Church and "bat condos" on State Game Lands. "There's no doubt some New York bats summer in Pennsylvania, and there's a possibility they could influence the health of some maternity colonies," von Oettingen said. "So it will be important for Game Commission biologists to monitor the population and health of their colonies."

The USFWS plans to continue facilitating and coordinating the regional response to WNS, and is looking for sources of additional funding to help states sort out what's happening within their borders. It also will continue to analyze suspect bats at its laboratories and coordinate to have other leading laboratories assist in this effort.

In Pennsylvania, Turner said the Game Commission will focus on summer maternity roosts and prepare for monitoring bats heading into hibernacula in the fall. He also noted Northeastern bat biologists will meet in June to establish priorities for collecting data at hibernacula this fall and winter, and brainstorm for funding to help defray the cost of additional fieldwork. Without supplemental funding or manpower assistance from other states, however, there will be a limit to how much fieldwork the Game Commission can accomplish on this important front.

Bats are a tremendous asset to wildlife communities, and humans. Collectively, they eat insects by the tons and spare Pennsylvanians from myriad backyard flying pest and crop-damage issues. Unfortunately, people know more about elephants than they do bats. So misinformation about bats often overshadows the good they do and their importance in Pennsylvania's biodiversity. Fore more information on bats, visit the Game Commission's website at http://www.pgc.state.pa.us. To learn more about WNS, visit the USFWS's we
'/>"/>

SOURCE Pennsylvania Game Commission
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AHF Seeks White House Clarification After Press Room Flap Over CDCs HIV Numbers
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
4. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)...IPPENHAM, England, October 7 /PRNewswire-FirstCall... Index: 4565) and Vectura,Group plc ("Vectura"; LS...evaluating the efficacy, safety and tolerability o...uropean Respiratory Society (ERS) in Berlin,Germa...bromide), a novel,inhaled long-acting muscarinic a...
(Date:10/6/2008)... 6 /PRNewswire-USNewswire/ -- "A return to the use...opment is without scientific,justification," accor...rnatives to Laboratory Animals (ATLA). "An Assessm...earch" concludes that vaccine responses in,chimpan...d that claims of,chimpanzees, critical role and im...
(Date:10/6/2008)...video clips feature children, parents discussing c...ETHESDA, Md., Oct. 6 /PRNewswire-USNewswire/ -- Fr...rch in children saves lives and improves their,hea...al Institutes of,Health (NIH), "Children and Clini...es.nhlbi.nih.gov ), offers parents and health,care...
(Date:10/6/2008)...m Phase 3b Studies with Durezol Dosed Prior to Sur...Therapeutics, Inc., a,privately held ophthalmic-fo...hat Durezol(TM) (difluprednate ophthalmic emulsion...ich was approved by the U.S. Food and,Drug Adminis...icosteroid,indicated for the treatment of inflamma...
Breaking Medicine Technology:NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5Research Attributes Lack of HIV/AIDS Vaccine to Use of Chimpanzees 2Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 2Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 3Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 2Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 5Innovative Uses of Technology to Improve Health for Poor and Vulnerable People to be Explored at Rockefeller Foundation Conference 20872 1Innovative Uses of Technology to Improve Health for Poor and Vulnerable People to be Explored at Rockefeller Foundation Conference 20872 2Innovative Uses of Technology to Improve Health for Poor and Vulnerable People to be Explored at Rockefeller Foundation Conference 20872 3Innovative Uses of Technology to Improve Health for Poor and Vulnerable People to be Explored at Rockefeller Foundation Conference 20872 4Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 5739 1Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 5739 2Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 5739 3Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 5739 4Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 5739 5OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer 20869 1OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer 20869 2OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer 20869 3Latest Advances in Infection Prevention and Control to be Presented in Denver CO at Worlds Largest Annual Infection Prevention Conference June 15 19 20866 1
...rimary Endpoint of Improvement in Overall,Survival...rstCall/ --,Allos Therapeutics, Inc. today announc...otal Phase 3 study of Efaproxyn ,(efaproxiral) plu...th brain metastases originating from breast cancer... of demonstrating a,statistically significant impr...
...2007 /PRNewswire-FirstCall/ -- Anadys,Pharmaceutic...to,the discovery, development and commercializatio...s and cancer, announced today that it,has nominate...s an,orally-administered direct antiviral for the ...tion. , "We have identified a small-molecule, non-...
Other Medicine Technology:Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 2Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 3Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 4Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 5Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 6Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 2Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 3Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 4
(Date:10/6/2008)...de effects can affect length of stay, study says ,...Simple changes to hospital procedures can signific...e on opiates to relieve pain, a new study reveals.... 14 U.S. children,s hospitals, documented a 67 per...in relievers under these new procedures. , The...
(Date:10/6/2008)...ased resource designed to engage and educate viewe...ns including Health Savings Accounts (HSAs), Healt...ing Accounts (FSAs), has partnered with sister com...ices in concert with its existing direct-to-broker... MINNEAPOLIS (Business Wire EON) Oc...
(Date:10/6/2008)...eukemia Victim Ernie Davis, Is, Spokesperson for T...ght(R) Walk, WHI...s, a 1960s,football hero who was the first African...t of the new film from Universal Pictures, The Exp...ercame seemingly insurmountable,obstacles to becom...
(Date:10/6/2008)... Today, PARI Pharma GmbH will,unveil a prototype C...le,dose ampoules to control medication used in the...-dose ampoule that is required to operate the,nebu...ets an unmet need by,reducing the risk of using th...ying filling procedures, improving dose uniformity...
Breaking Medicine News(10 mins):Health News:Hospital Fixes Cut Opiate Errors in Kids 2Health News: LearnCDHC Bridges Education Gap on Consumer Directed Healthcare : Interactive Web resource engages and educates consumers about consumer-directed healthcare 2Health News: LearnCDHC Bridges Education Gap on Consumer Directed Healthcare : Interactive Web resource engages and educates consumers about consumer-directed healthcare 3Health News:Release of Universal Film The Express Draws Attention to Tragedy of Lives Cut Short by Blood Cancer 2Health News:PARI Pharma Unveils Closed System Using eFlow Technology at Medical Plastics Conference 2
...omen had about a 20 percent lower chance of develo... new research bolsters the theory that the female ...al cancer. Dr. Carlo La Vecchia, who led the s...uspected that estrogen in the pill could protect a...
...re is poorly controlled. Drugs and lifestyle modif...rtension) yet these measures are not being taken b...he Baylor School of Medicine, Houston, Texas, doct...00 adults over 25 and found that 27 per cent had h...
...anization for Scientific Research (NWO) discovered...tance to disease if they took extra zinc in additi..., zinc was largely ignored due to the difficulty i...Scientists now know that zinc deficiency leads to ...
...er these days, wonder premature memory loss is no... too much work causing lack of concentration, memo...erations in memory and neurotransmitters are found...nson's disease and Alzheimer's disease. // The fun...
Other Medicine News:
The IntraStent DoubleStrut Biliary Stent represents a completely new direction in stent design. The combination of parallel struts and unique cell geometry provide unparalleled performance.
The Smart Check Syphilis Device is a qualitative membrane device based immunoassay for the detection of TP (Treponema Pallidum) antibodies in whole blood/serum/plasma. For professional in vitro diagn
Bio-Quant, Inc. OneStep hCG InstaTest is an immunochromatographic assay designed for qualitative determination of human chorionic gonadotropin (hCG) in urine for early detection of pregnancy.
OneStep Midstream Urine hCG Pregnancy InstaTest is a test kit for the determination of hCG(Human Chorionic Gonadotropin) in urine specimens. This test kit is used to obtain a visual, qualitative resu
Medicine Products: